What is the recommended dosing regimen of ketamine as a dissolvable (sublingual/oral) tablet for pain management in an adult without hepatic or renal impairment, no history of psychosis, and not receiving other NMDA‑antagonist drugs?

Ketamine Dissolvable Tablets for Pain Management: No FDA-Approved Formulation Exists

There is currently no FDA-approved dissolvable (sublingual or oral) ketamine tablet formulation for pain management. The FDA-approved ketamine products are limited to injectable formulations for anesthesia 1 and esketamine nasal spray (Spravato) for treatment-resistant depression—not for pain management.

Critical Context: Off-Label Use Only

Any use of ketamine tablets/lozenges for pain represents off-label prescribing using compounded formulations. The evidence base is limited to small studies and case series, not large randomized trials.

Dosing Recommendations Based on Available Evidence

Starting Dose for Ketamine-Naive Patients

Begin with 0.5 mg/kg of racemic ketamine (or 0.25 mg/kg of S-ketamine) as a single dose 2. For a 70 kg adult, this translates to approximately 35 mg of racemic ketamine per dose.

Titration Strategy

• Increase by the same increment (0.5 mg/kg) if pain relief is inadequate 2
• Administer 3-4 times daily for continuous analgesic effect 2, 3
• Target dose range: 25-300 mg/day total (most commonly 0.5 mg/kg TID = ~105-150 mg/day for average adult) 4, 3

Route-Specific Considerations

Sublingual administration provides faster onset but more adverse effects:

• Time to first effect: 6.6 minutes sublingual vs. 13.1 minutes oral 5
• Time to meaningful pain relief: 10.8 minutes sublingual vs. 29.4 minutes oral (p=0.02) 5
• Higher adverse event rate with sublingual route (p=0.02) 5
• Overall analgesic efficacy similar between routes 5

Practical recommendation: Start with oral administration to minimize adverse effects, reserve sublingual for breakthrough pain requiring rapid onset.

Treatment Duration and Monitoring

• Initial trial: 7-90 days to assess efficacy 3
• Evidence supports use up to 3 months initially, with some patients continuing for years 6, 2
• Pain reduction typically 60-70% in responders 6, 3
• Mean pain scores decrease from 7.72/10 to 3.2/10 over 30-90 days 3

Safety Thresholds and Adverse Effects

Critical Dose Limit

Weight-based doses above 6 mg/kg correspond with increased adverse effects 4. Stay well below this threshold.

Common Adverse Effects

• Psychotomimetic experiences (dissociation, dream-like states)
• Dizziness and somnolence
• Nausea
• Generally mild and transient 4, 6

Monitoring Requirements

• Liver function tests: Aminotransferase elevations can occur but are typically mild and transient 7
• Routine liver monitoring justified throughout treatment given rare cases of impaired liver function 7
• Blood pressure monitoring (ketamine can cause hypertension) 8

Clinical Context from Guidelines

The 2025 NCCN Cancer Pain Guidelines acknowledge ketamine as an NMDA antagonist with limited data for cancer pain management 9. A 2020 geriatrics guideline notes ketamine is used by specialists in palliative care, pain management, and emergency medicine due to risks of psychotomimetic effects and hypertension 8.

Ketamine should be reserved for refractory pain unresponsive to conventional analgesics 9, 4. It functions best as part of multimodal analgesia, particularly for neuropathic pain with opioid-refractory features 8, 9.

Practical Algorithm

1. Confirm indication: Refractory chronic pain (neuropathic preferred), failed conventional therapies
2. Screen contraindications: Active psychosis, uncontrolled hypertension, severe hepatic impairment
3. Baseline labs: Liver function tests, blood pressure
4. Start oral ketamine 0.5 mg/kg (~35 mg for 70 kg adult) TID
5. Titrate by 0.5 mg/kg increments every 3-7 days based on response
6. Target total daily dose: 1.5-2 mg/kg/day divided TID-QID (~105-140 mg/day for 70 kg adult)
7. Maximum: Do not exceed 6 mg/kg/day (~420 mg/day for 70 kg adult)
8. Monitor: Pain scores weekly, liver function monthly, blood pressure at each visit
9. Reassess at 30-90 days: Continue if ≥30% pain reduction, discontinue if ineffective

Key Caveats

• Compounded formulations lack FDA oversight for quality, purity, and consistency
• Long-term safety data are limited 4, 2
• Opioid-sparing effect: Patients on concurrent opioids show better ketamine response (7% failure rate vs. 36% in opioid-naive, p<0.02) and fewer adverse effects (33% vs. 68%, p<0.01) 6
• Injectable ketamine can be administered orally by having patients swallow the injection solution 2